Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>JPM Lifts WUXI BIO (02269.HK) TP to $13; 'US Biosecure Act' Expected to Have Results in ~2 Wks
Recommend 11 Positive 26 Negative 10 |
||||
|
||||
|
JPMorgan released a report raising its target price for WUXI BIO (02269.HK) from $11 to $13 with a Neutral rating. The broker anticipated that the "US Biosecure Act" would have results in about two weeks. The best way for the "Biosecure Act" to pass through the US Congress this year is to be included in the NDAA 2025 (National Defense Authorization Act) bill, which must be passed in December, said the broker. Experts from JPMorgan predicted that the NDAA bill could be voted on in December, meaning a "conferencing" version of the NDAA bill could be seen in early December. If the "Biosecure Act" is attached to the "conferencing" version of the NDAA bill, it is likely to pass this year. Conversely, if the bill is not attached, the likelihood of it passing through the US Congress this year will become quite slim. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
